Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986207 |
Synonyms | |
Therapy Description |
BMS-986207 is a human monoclonal antibody against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986207 | BMS986207|BMS 986207 | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 | BMS-986207 is a human monoclonal antibody against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02913313 | Phase Ib/II | BMS-986207 + Nivolumab BMS-986207 | A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers | Completed | USA | ROU | CAN | AUS | ARG | 3 |
NCT04150965 | Phase Ib/II | Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Active, not recruiting | USA | 0 |